Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Site-001, Farmington, Connecticut Site-003, Miami Lakes, Florida Site-011, Miami Lakes, Florida Site-013, Orlando, Florida Site-005, Pembroke Pines, Florida Site-008, Lawrenceville, Georgia Site-009, Hinsdale, Illinois Site-012, Indianapolis, Indiana Site-006, Chesterfield, Missouri Site-002, Dakota Dunes, South Dakota